Navigation Links
Signal Genetics and Pronto Diagnostics Announce Distribution Agreement
Date:4/4/2011

NEW YORK and TEL AVIV, Israel, April 4, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC, and Pronto Diagnostics Ltd, both of which are privately held predictive genetic testing companies focused on oncology, announced that they have entered into a Distribution Agreement whereby Pronto will be the exclusive representative and distributor for Signal's Myeloma Prognostic Risk Signature (MyPRS) test in Israel.  

According to Joe Hernandez, CEO of Signal Genetics, "The Agreement with Pronto Diagnostics represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology." Signal's MyPRS test is performed at the company's CLIA lab located in Little Rock, Arkansas and has been adopted by several highly reputable academic cancer centers throughout the U.S.

Dr. Nir Navot, Chairman and CTO of Pronto Diagnostics affirmed: "Our agreement with Signal Genetics allows us to provide a valuable prognostic tool to Israeli hematologists who treat Myeloma patients, in line with our commitment to increasing personalization of treatment for cancer patients".

About Signal Genetics

Signal Genetics, the parent company of Myeloma Health, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predictive outcome of disease stage, odds of relapse, and the optimal treatment regimen based on their specific genetic expression profile. Additional information is available at www.signalgenetics.com.

About Pronto Diagnostics

Pronto Diagnostics is a privately held company based in Tel Aviv that provides services for molecular diagnosis of disease with a focus on oncology, including the development and distribution of genetic testing kits.  Pronto has similar distribution relationships with several molecular diagnostic companies including Ipsogen, Pathwork Diagnostics, and Epigenomics. Additional information is available at www.prontodiagnostics.com.


'/>"/>
SOURCE Signal Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test
2. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
3. Signal Genetics Announces Establishment of Scientific Advisory Board
4. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
5. TRINAMIC Teams with Actel's SmartFusion™ Intelligent Mixed Signal FPGAs for Motion Control
6. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
7. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
8. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
9. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
10. Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
11. Revealing the regulating mechanism behind signal transduction in the brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):